Dtsch Med Wochenschr 2011; 136(22): 1194-1196
DOI: 10.1055/s-0031-1280539
Rheumatologie | Commentary
Rheumatologie
© Georg Thieme Verlag KG Stuttgart · New York

Vaskulitis

VasculitisM. Fleck1 , B. Hellmich2
  • 1Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Regensburg, und Klinik für Rheumatologie/Klinische Immunologie, Asklepios Klinikum Bad Abbach
  • 2Klinik für Innere Medizin, Kreiskliniken Esslingen gGmbH, Klinik Plochingen
Further Information

Publication History

Publication Date:
24 May 2011 (online)

    Permissions and Reprints

Schlüsselwörter

Vaskulitis - ANCA - EULAR-Empfehlungen - Wegener-Granulomatose - Riesenzellarteriitis - Takayasu-Arteriitis - Kryoglobulinämie

Keywords

vasculitis - ANCA - EULAR recommendations - Wegener's granulomatosis - giant cell arteritis - Takayasu's arteritis - cryoglobulinemia

Literatur

  • 1 Cartin-Ceba R, Golbin J, Keogh K. et al . Rituximab for induction and maintenance in ANCA-associated vasculitis.  Arthritis Rheum. 2010;  62 (Suppl.) S283
    Search in Google Scholar
  • 2 Dammacco F, Tucci F A, Lauletta G. et al . Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia.  Blood. 2010;  116 343-353
    Search in Google Scholar
  • 3 Hiemstra T F, Walsh M, Mahr A. et al . Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis.  J Am Med Assoc. 2010;  304 2381-2388
    Search in Google Scholar
  • 4 Jones R, Smith R, Guerry M Y. et al . Protocollized versus non-protocollized rituximab treatment for refractory ANCA-associated vasculitis.  Arthritis Rheum. 2010;  62 (Suppl.) S283
    Search in Google Scholar
  • 5 Jones R B, Tervaert J W. et al . Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.  N Engl J Med. 2010;  363 211-220
    Search in Google Scholar
  • 6 Mukhtyar C, Guillevin L, Cid M C. et al . EULAR recommendations for the management of large vessel vasculitis.  Ann Rheum Dis. 2009;  68 318-323
    Search in Google Scholar
  • 7 Mukhtyar C, Guillevin L, Cid M C. et al . EULAR recommendations for the management of primary small and medium vessel vasculitis.  Ann Rheum Dis. 2009;  68 310-317
    Search in Google Scholar
  • 8 Saadoun D, Resche Rigon M, Sene D. et al . Rituximab plus Peg-Interferon-alpha/ribavirin with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.  Blood. 2010;  116 326-334
    Search in Google Scholar
  • 9 Stone J H, Merkel P A. et al . Rituximab versus cyclophosphamide for ANCA-associated vasculitis.  N Engl J Med. 2010;  363 221-232
    Search in Google Scholar
  • 10 Terrier B, Launay D, Kaplanski G. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis.  Arthritis Care Res. 2010;  62 1787-1795
    Search in Google Scholar
  • 11 Walsh M, Merkel P A, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis.  Arthritis Care Res. 2010;  62 1166-1173
    Search in Google Scholar

Prof. Dr. med. Bernhard Hellmich

Kreiskliniken Esslingen gGmbH Klinik Plochingen
Akademisches Lehrkrankenhaus der Universität Tübingen
Klinik für Innere Medizin
(Allgemeine Innere Medizin, Rheumatologie und Klinische Immunologie, Intensivmedizin)

Am Aussichtsturm 5

73207 Plochingen

Email: b.hellmich@kk-es.de